Clinical Trials Logo

PCSK9 clinical trials

View clinical trials related to PCSK9.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05191342 Recruiting - PCSK9 Clinical Trials

Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis

Start date: November 1, 2021
Phase:
Study type: Observational

Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.